These findings are consistent with previous reports demonstrating that the use of a CD39 inhibitor effectively relieved the tumor-induced suppression of CD4 and CD8 T cell proliferation [41] and that the CD39-CD73 axis plays a role in the suppressor activity of Treg cells [10,42,43]. The gene discussed is ENTPD1; the disease is neoplasm.